Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

References

• Vangeli E, Bakhshi S, Baker A, et al. A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther. 2015;32(11):983–1028. doi:10.1007/s12325-015-0256-7
   PubMed Web of Science ®Google Scholar
• Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. Rheumatol Int. 2017;37(9):1551–1557.
   PubMed Web of Science ®Google Scholar
• Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV Jr. Incidence and prevalence of Crohn’s Disease and ulcerative colitis in Olmsted county, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol. 2017;15(6):857–863.
   PubMed Web of Science ®Google Scholar
• Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251–260.
   PubMed Web of Science ®Google Scholar
• Hanauer SB. The expanding role of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010;7(2):63–64.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutical Companies. REMICADE (Infliximab) Highlights of Prescribing Information; 2018.
   Google Scholar
• Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics. 2019;13:139–178.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Biosimilar and interchangeable products. 2017; https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products. Accessed December 17, 2019.
   Google Scholar
• CELLTRION, Inc. INFLECTRA^® (Infliximab-Dyyb) Highlights of Prescribing Information; 2019.
   Google Scholar
• Amgen Inc. AVSOLA (Infliximab-Axxq) Highlights of Prescribing Information; 2019.
   Google Scholar
• Samsung Bioepis Co. RENFLEXIS (Infliximab-Abda) Highlights of Prescribing Information; 2019.
   Google Scholar
• Pfizer Ireland Pharmaceuticals. IXIFI (Infliximab-Qbtx) Highlights of Prescribing Information; 2020.
   Google Scholar
• Teeple A, Ellis LA, Huff L, et al. Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States. Curr Med Res Opin. 2019;35(4):611–617. doi:10.1080/03007995.2019.1571296
   PubMed Web of Science ®Google Scholar
• Wolf D, Skup M, Yang H, et al. Clinical outcomes associated with switching or discontinuation from Anti-TNF inhibitors for nonmedical reasons. Clin Ther. 2017;39(4):849–862. doi:10.1016/j.clinthera.2017.03.005
   PubMed Web of Science ®Google Scholar
• Glintborg B, Sorensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76(8):1426–1431.
   PubMed Web of Science ®Google Scholar
• Scherlinger M, Germain V, Labadie C, et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Joint Bone Spine. 2018;85(5):561–567.
   PubMed Web of Science ®Google Scholar
• Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet (London, England). 2017;389(10086):2304–2316.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Choe JY, Prodanovic N, et al. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, Phase III transition study. Ann Rheum Dis. 2018;77(2):234–240.
   PubMed Web of Science ®Google Scholar
• Avouac J, Molto A, Abitbol V, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: the experience of Cochin University Hospital, Paris, France. Semin Arthritis Rheum. 2018;47(5):741–748.
   PubMed Web of Science ®Google Scholar
• Gentileschi S, Barreca C, Bellisai F, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677-1683. Expert Opin Biol Ther. 2016;16(10):1311–1312.
   PubMed Web of Science ®Google Scholar
• Tweehuysen L, van den Bemt BJF, van Ingen IL, et al. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol. 2018;70(1):60–68.
   PubMed Web of Science ®Google Scholar
• Lund JL, Horvath-Puho E, Komjathine Szepligeti S, et al. Conditioning on future exposure to define study cohorts can induce bias: the case of low-dose acetylsalicylic acid and risk of major bleeding. Clin Epidemiol. 2017;9:611–626.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Fleischmann R, Jairath V, Mysler E, Nicholls D, Declerck P. Nonmedical switching from originators to biosimilars: does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology? Rheumatol Ther. 2020;7(1):35–64.
   PubMed Web of Science ®Google Scholar
• Mahmmod S, Schultheiss J, Mahmmod N, Tan A, Dijkstra G, Fidder H. P1809 - Reverse switching to originator infliximab may be considered in patients with inflammatory bowel diseases experiencing new side effects or loss of response after switching to a CT-P13 biosimilar. Paper presented at: United European Gastroenterology Week 2019.
   Google Scholar
• Ho SL, Niu F, Pola S, Velayos FS, Ning X, Hui RL. Effectiveness of switching from reference product infliximab to infliximab-Dyyb in patients with inflammatory bowel disease in an integrated healthcare system in the United States: a retrospective, propensity score-matched, non-inferiority cohort study. BioDrugs. 2020.
   Web of Science ®Google Scholar
• Phillips K, Juday T, Zhang Q, Keshishian A. SAT0172 Economic outcomes, treatment patterns, and adverse events and reactions for patients prescribed infliximab or ct-p13 in the Turkish population. Ann Rheum Dis. 2017;76(Suppl 2):835.
   Google Scholar
• Reuber K, Kostev K. Prevalence of switching from two anti-TNF biosimilars back to biologic reference products in Germany. Int J Clin Pharmacol Ther. 2019;57(6):323–328.
   PubMed Web of Science ®Google Scholar
• Yazici Y, Xie L, Ogbomo A, et al. Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab. Biologics. 2018;12:127–134.
   PubMed Web of Science ®Google Scholar
• Madenidou A, Jeffries A, Varughese S, et al. Switching patients with inflammatory arthritis from Etanercept (Enbrel®) to the biosimilar drug, SB4 (Benepali®): a single-centre retrospective observational study in the UK and a review of the literature. Mediterranean J Rheumatol. 2019;30(Supp 1):69–75.
   Google Scholar
• Alten R, Neregard P, Jones H, et al. SAT0161 Preliminary real world data on switching patterns between etanercept, its recently marketed biosimilar counterpart and its competitor adalimumab, using swedish prescription registry. Ann Rheum Dis. 2017;76(Suppl):2.
   Google Scholar
• Mahmmod S, Schultheiss J, Tan A, et al. Reasons for and effectiveness of switching back to originator infliximab after a prior switch to CT-P13 biosimilar. J Crohn’s Colitis. 2020;14(Suppl):1.
   Google Scholar
• Brown CN, McCann E. Cost of switching from an originator biologic (Remicade) to a biosimilar. Value Health. 2016;19(7):A581.
   Web of Science ®Google Scholar
• Liu Y, Yang M, Garg V, Wu EQ, Wang J, Skup M. Economic impact of non-medical switching from originator biologics to biosimilars: a systematic literature review. Adv Ther. 2019.
   Web of Science ®Google Scholar
• Guerra Veloz MF, Belvis Jimenez M, Valdes Delgado T, et al. Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data. Therap Adv Gastroenterol. 2019;12:1756284819858052.
   Web of Science ®Google Scholar
• Hoivik ML, Buer LCT, Cvancarova M, et al. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population. Scand J Gastroenterol. 2018;53(6):692–699.
   PubMed Web of Science ®Google Scholar
• Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA. Maintained clinical remission in ankylosing spondylitis patients switched from reference infliximab to its biosimilar: an 18-month comparative open-label study. J Clin Med. 2019;8:7.
   Web of Science ®Google Scholar
• Rezk MF, Pieper B. Treatment outcomes with biosimilars: be aware of the nocebo effect. Rheumatol Ther. 2017;4(2):209–218.
   PubMed Web of Science ®Google Scholar
• Teeple A, Ginsburg S, Howard L, et al. Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States. Curr Med Res Opin. 2019;35(4):603–609.
   PubMed Web of Science ®Google Scholar
• El-Gabalawy H, Guenther LC, Bernstein CN. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl. 2010;85:2–10.
   PubMedGoogle Scholar